Existing Cancer Drug Could Be HIV Cure

A groundbreaking revelation from Melbourne, Australia, offers newfound hope in the fight against HIV. Recent research, spearheaded by two renowned institutions, the Walter and Eliza Hall Institute (WEHI) and The Peter Doherty Institute for Infection and Immunity (Doherty Institute), has unearthed the potential of an existing blood cancer drug to serve as a potential HIV cure.

Unveiling the Covert Threat of HIV

To appreciate the significance of this discovery, it’s vital to understand the challenges posed by HIV, a virus that affects an estimated 39 million people globally, including over 29,400 Australians. HIV primarily targets CD4+ T cells, a type of white blood cell essential for our immune system. Within these cells, HIV can lay dormant, poised to reactivate if not properly addressed.

The issue lies in current treatments, like antiretroviral therapy (ART), which can suppress the virus but cannot eliminate these dormant HIV cells. Consequently, individuals living with HIV must remain on medication for life, or the virus quickly resurfaces.

A Glimmer of Hope: Venetoclax

Enter venetoclax, originally designed to combat blood cancer. Researchers at WEHI and the Doherty Institute have identified venetoclax as a potential solution to target and eliminate these dormant HIV-infected cells. In their research, they administered this drug to advanced pre-clinical models of HIV and made a remarkable observation: venetoclax delayed the reappearance of the HIV virus, even without the use of ART.

Think of it this way: While ART keeps HIV in check, venetoclax holds the promise of potentially eradicating the hidden HIV cells, moving us one step closer to finding a cure. Dr. Philip Arandjelovic from WEHI underscored, “Each advancement in postponing the resurgence of this virus brings us nearer to preventing its return in individuals living with HIV.”

Unveiling Venetoclax’s Potential

Venetoclax’s efficacy lies in its ability to selectively target infected cells by zeroing in on key survival proteins. It spares healthy cells while eliminating those infected with HIV. Furthermore, the drug significantly reduces the quantity of intact viral DNA in patient cells, signifying its potential effectiveness.

The Next Phase: Clinical Trials

The next chapter in this groundbreaking discovery involves clinical trials. These trials are slated to commence later this year in Denmark, with plans to expand to Melbourne in 2024. They will scrutinize venetoclax’s safety and effectiveness in individuals living with HIV who are already undergoing suppressive antiretroviral therapy.

Overseeing these trials will be Professor Sharon Lewin, Professor Marc Pellegrini, and Dr. Thomas Rasmussen, distinguished experts in infectious diseases and immune defense.

A Holistic Approach to an HIV Cure

While venetoclax exhibits immense promise, it’s crucial to bear in mind that a single drug may not suffice to entirely eliminate HIV. Researchers have also uncovered that venetoclax could be more potent when combined with another drug targeting the same pathway. This combination might extend the delay in viral resurgence while necessitating a shorter duration of venetoclax treatment.

A Collaborative and Innovative Journey

Venetoclax’s journey from its initial groundbreaking discovery in 1988 by Professor David Vaux AO to its potential as an HIV cure exemplifies the power of collaboration. It is the result of a partnership between WEHI and major companies like Roche, Genentech, and AbbVie. This drug’s development took place under the auspices of Roche, Genentech, and AbbVie, with substantial contributions from Australia.

A Promising Future

As we gaze into the future, a world where millions of individuals living with HIV may no longer require lifelong medication comes into view. This discovery represents a significant stride in the battle against HIV and brings newfound hope to those affected by this disease.

In conclusion, recent research conducted in Melbourne, Australia, under the leadership of the Walter and Eliza Hall Institute and The Peter Doherty Institute for Infection and Immunity has unveiled a new path forward in the fight against HIV. Venetoclax, an existing blood cancer drug, has demonstrated substantial potential in targeting dormant HIV cells, opening up the possibility of a cure. Clinical trials are on the horizon, bringing us closer to a future where HIV could be conquered.

You can find more news on our site.